Eam Global Investors LLC Biocryst Pharmaceuticals Inc Transaction History

Eam Global Investors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.89 - $17.88 $826,509 - $1.87 Million	-104,754 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $1.21 Million - $2.07 Million	104,754 New	104,754 $1.7 Million
Q4 2021 Feb 11, 2022	SELL	$11.18 - $15.46 $1.18 Million - $1.64 Million	-105,976 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $725,974 - $901,720	-51,089 Reduced 32.53%	105,976 $1.52 Million
Q2 2021 Aug 13, 2021	BUY	$9.5 - $17.24 $1.49 Million - $2.71 Million	157,065 New	157,065 $2.48 Million
Q3 2020 Nov 13, 2020	SELL	$3.43 - $5.53 $1.19 Million - $1.93 Million	-348,249 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$1.9 - $5.61 $661,673 - $1.95 Million	348,249 New	348,249 $1.66 Million
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $524,379 - $1.65 Million	-180,199 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$6.51 - $9.6 $1.17 Million - $1.73 Million	180,199 New	180,199 $1.45 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Global Investors LLC with notifications on news.